NASDAQ:REPL Replimune Group Q4 2026 Earnings Report $12.96 -0.51 (-3.79%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$12.82 -0.15 (-1.12%) As of 09:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Replimune Group EPS ResultsActual EPS-$0.76Consensus EPS -$0.66Beat/MissMissed by -$0.10One Year Ago EPSN/AReplimune Group Revenue ResultsActual RevenueN/AExpected Revenue$3.57 millionBeat/MissN/AYoY Revenue GrowthN/AReplimune Group Announcement DetailsQuarterQ4 2026Date6/29/2026TimeBefore Market OpensConference Call DateMonday, June 29, 2026Conference Call Time8:00AM ETUpcoming EarningsReplimune Group's Q2 2027 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Replimune Group Earnings HeadlinesREPL UPCOMING DEADLINE: Levi & Korsinsky Alerts Replimune Group, Inc. Stockholders of Securities Class Action - Contact the FirmSeptember 23 at 10:07 AM | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPLSeptember 22 at 6:00 PM | globenewswire.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.September 24 at 1:00 AM | Porter & Company (Ad)Portnoy Law Firm Announces Class Action on Behalf of Replimune Group, Inc. InvestorsSeptember 22 at 1:27 PM | globenewswire.comREPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallStSeptember 22 at 11:19 AM | globenewswire.comREPL Stockholders with Significant Losses Should Contact Robbins LLP Before the Pending October 5, 2026 Lead Plaintiff Deadline for Information About Recovering Their LossesSeptember 18, 2026 | prnewswire.comSee More Replimune Group Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Replimune Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Replimune Group and other key companies, straight to your email. Email Address About Replimune GroupReplimune Group (NASDAQ:REPL) is a biotechnology company focused on developing oncolytic immunotherapies designed to stimulate the immune system to recognize and attack cancer. The company’s approach is based on a proprietary platform that uses genetically engineered herpes simplex virus type 1 (HSV-1) to selectively replicate in tumors and deliver immune-activating payloads. Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an investigational oncolytic immunotherapy being evaluated in clinical studies for solid tumors, including melanoma and cutaneous squamous cell carcinoma. The company is also developing additional candidates, including RP2 and RP3, which are designed to incorporate further immune-stimulating mechanisms and potentially address a broader range of cancers. Founded in 2015 and headquartered in Woburn, Massachusetts, Replimune conducts research and clinical development activities through collaborations and trials involving patients in the United States and other international markets. The company’s leadership has included co-founder and Chief Executive Officer Philip Astley-Sparke, who has experience in biotechnology and oncology-focused drug development.View Replimune Group ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
